M.G. Mumolo
University of Pisa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M.G. Mumolo.
Digestive and Liver Disease | 2003
Francesco Costa; M.G. Mumolo; M. Bellini; M. R. Romano; L. Ceccarelli; P. Arpe; C. Sterpi; Santino Marchi; G. Maltinti
BACKGROUND/AIM Faecal calprotectin, a neutrophil granulocyte cytosol protein, is considered a promising marker of intestinal inflammation. We assessed and compared the faecal calprotectin concentration in patients with organic and functional chronic intestinal disorders. PATIENTS AND METHODS The study was carried out, using a commercially available ELISA test, measuring calprotectin in stool samples collected from 131 patients with inflammatory bowel diseases, 26 with intestinal neoplasms, 48 with irritable bowel syndrome and 34 healthy subjects. RESULTS Median faecal calprotectin was significantly increased in Crohns disease (231 microg/g, 95% confidence interval (CI) 110-353 microg/g), ulcerative colitis (167 microg/g, 95% CI 59-276 microg/g), and neoplasms (105 microg/g, 95% CI 0-272 microg/g), whereas normal values were found in patients with irritable bowel syndrome (22 microg/g, 95% CI 9-35 microg/g) and in healthy subjects (11 microg/g, 95% CI 3-18 microg/g). A positive correlation was observed with clinical activity scores in Crohns disease and ulcerative colitis. In both groups, patients with clinically active disease showed higher calprotectin levels than those observed in patients with quiescent disease (405 microg/g, 95% CI 200-610 microg/g vs. 213 microg/g, 95% CI 85-341 microg/g in CD patients, p<0.05, and 327 microg/g, 95% CI 104-550 microg/g vs. 123 microg/g, 95% CI 40-206 microg/g in UC patients, p<0.001). CONCLUSIONS Faecal calprotectin appears to be a promising and non-invasive biomarker of intestinal inflammation. If these findings are confirmed, it may provide a useful test for the diagnosis and follow up of inflammatory bowel diseases.
Alimentary Pharmacology & Therapeutics | 2001
Francesco Costa; M.G. Mumolo; M. Bellini; M. R. Romano; M. Manghetti; A. Paci; G. Maltinti; Santino Marchi
Helicobacter pylori has attracted increasing attention among gastroenterologists because of its pathogenic potential, stimulating the search for non‐invasive diagnostic tests.
Alimentary Pharmacology & Therapeutics | 2011
N. De Bortoli; Irene Martinucci; Paolo Piaggi; S. Maltinti; G. Bianchi; Eugenio Ciancia; Dario Gambaccini; F. Lenzi; Francesco Costa; G. Leonardi; A. Ricchiuti; M.G. Mumolo; M. Bellini; Corrado Blandizzi; Santino Marchi
Aliment Pharmacol Ther 2011; 33: 1019–1027
Digestive and Liver Disease | 2005
M. Bellini; Cesare Tosetti; Francesco Costa; Sonia Biagi; C Stasi; A Del Punta; P Monicelli; M.G. Mumolo; A. Ricchiuti; Paolo Bruzzi; Santino Marchi
Techniques in Coloproctology | 2013
M. Bellini; Dario Gambaccini; Stefano Salvadori; C. Tosetti; M.T. Urbano; Francesco Costa; P. Monicelli; M.G. Mumolo; A. Ricchiuti; N. De Bortoli; Santino Marchi
Minerva gastroenterologica e dietologica | 2003
M. Bellini; L. Rappelli; P. Alduini; C. Nisita; A. Barbanera; Francesco Costa; C. Mammini; M.G. Mumolo; Cristina Stasi; S. Cortopassi; Mauro Mauri; G. Maltinti; Santino Marchi
Techniques in Coloproctology | 2017
M. Bellini; Dario Gambaccini; Laura Bazzichi; Gabrio Bassotti; M.G. Mumolo; Bernardo Fani; Francesco Costa; A. Ricchiuti; N. De Bortoli; Marta Mosca; Santino Marchi
World Congresses of Gastroenterology, September 6-11,1998, Vienna | 1998
Francesco Costa; M. Bellini; C. Belcari; A. Tornar; A. Paci; M.G. Mumolo; M. R. Romano; M. Manghetti; P. Ciccorossi; S. Petruccelli; G. Maltinti; Santino Marchi
Digestive and Liver Disease | 2016
M. Bellini; A. Saviozzi; Dario Gambaccini; Lorenzo Bertani; A. Ricchiuti; M.T. Urbano; M.G. Mumolo; Francesco Costa; N. De Bortoli; Laura Bazzichi; Marta Mosca; Santino Marchi
Digestive and Liver Disease | 2006
Cristina Stasi; Antonio Frisoli; M. Bellini; S. Taddei; Francesco Costa; Sonia Biagi; S. Favilla; M.G. Mumolo; A. Ricehiuti; Santino Marchi
